DiSilvestro Looks at PARP Inhibition as First-Line Maintenance Therapy in Advanced Ovarian Cancer
A recent study conducted by Robert DiSilvestro, MD, suggests that PARP inhibition may be an effective first-line maintenance therapy for patients with advanced ovarian cancer. The study evaluated the use of PARP inhibitors, specifically rucaparib, as a maintenance therapy for patients who had responded well to platinum-based chemotherapy. The results showed that patients who received rucaparib had a longer progression-free survival compared to those who received a placebo. Furthermore, the study found that the benefits of rucaparib were consistent across all subgroups, including those with BRCA mutations and those without. These findings suggest that PARP inhibition could be a viable option for first-line maintenance therapy in patients with advanced ovarian cancer.